Evidence map›Paper›PMID 29854625›Full record

ArticleToxicology reports2018

Black bean peptides inhibit glucose uptake in Caco-2 adenocarcinoma cells by blocking the expression and translocation pathway of glucose transporters.

Luis Mojica, Diego A Luna-Vital, Elvira Gonzalez de Mejia

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Toxicology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05869344 (Black Bean), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05869344 nacompletednot on this map

Black Bean (Phaseolus Vulgaris L.) Protein Hydrolysates Reduce Acute Postprandial Glucose Levels in Prediabetes and Normal Glucose Tolerance Adults

TypeinterventionalSponsorClaudia Luévano-ContrerasRan2018 to 2022Enrolled28ConditionsPreDiabetesArmsBlack bean protein hydrolysates (BPH), Commercial non-caloric beverage
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Nutrients · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. BIOPEP-UWM Database of Bioactive Peptides: Current Opportunities.International journal of molecular sciences · 2019
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Luis MojicaDepartment of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, IL, 61801, United States.
Diego A Luna-VitalDepartment of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, IL, 61801, United States.
Elvira Gonzalez de MejiaDepartment of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, IL, 61801, United States.
University of Illinois Urbana-Champaign · USCentro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective was to evaluate the effect of black bean protein fraction (PFRA), and its derived peptides on glucose uptake, SGLT1 and GLUT2 expression and translocation on Caco-2 cells. The effect of treatments was evaluated on glucose uptake, protein expression and localization and gene expression on Caco-2 cells. PFRA (10 mg/mL) lowered glucose uptake from 27.4% after 30 min to 33.9% after 180 min of treatment compared to untreated control (p < 0.05). All treatments lowered GLUT2 expression after 30 min of treatment compared to untreated control (31.4 to 48.6%, p < 0.05). Similarly, after 24 h of treatment, GLUT2 was decreased in all treatments (23.5% to 48.9%) (p < 0.05). SGLT1 protein expression decreased 18.3% for LSVSVL (100 μM) to 45.1% for PFRA (10 mg/mL) after 24 h. Immunofluorescence microscopy showed a decrease in expression and membrane translocation of GLUT2 and SGLT1 for all treatments compared to untreated control (p < 0.05). Relative gene expression of SLC2A2 (GLUT2) and SLC5A1 (SGLT1) was downregulated significantly up to two-fold change compared to the untreated control after 24 h treatment. Black bean protein fractions are an inexpensive, functional ingredient with significant biological potential to reduce glucose uptake and could be used as an adjuvant in the treatment of colorectal cancer.

Indexed as

2-NBDG, 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-d-glucose2-NBDG PubChem CID: 6711157A, alanineAMPK, 5′ adenosine monophosphate-activated protein kinaseAU, arbitrary unitsBlack bean protein fractionBPI, bean protein isolateColorectal cancerE, glutamic acidF, phenylalanineGlucose: PubChem CID: 10954115Glucose uptakeGLUT2GLUT2, glucose transporter 2I:K, lysineL, leucineN, asparagineP FRA, protein fractionsPhloretin: PubChem CID: 4788PHL, phloretinPKC, protein kinase C IIP, prolineSD, standard deviationSGLT1SGLT1, sodium-dependent glucose cotransporter 1S, serineT, threonineV, valineWZB117, 3-fluoro-1,2-phenylene bis (3-hydroxybenzoate)

Identifiers

PMID29854625
PMCPMC5977767
OpenAlexW2802808677

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.